Some products were only tested chemically and were not tested for sterility or endotoxins
In pre-clinical laboratory models, MOTS-c has demonstrated a wide range of effects relevant to metabolic science, exercise physiology, and longevity research: Reverses diet-induced insulin resistance studies have shown MOTS-c can improve insulin sensitivity in skeletal muscle in high-fat diet and obesity models Improves glucose metabolism shown to lower fasting blood glucose levels across multiple diabetic animal models (T1D, T2D, gestational diabetes) Enhances physical performance pre-clinical research demonstrated significantly improved exercise capacity in young, middle-aged, and old mice following MOTS-c treatment Reduces age-related muscle decline late-life intermittent MOTS-c treatment (3x/week) increased physical capacity and healthspan markers in aged mouse models Supports cardiac function research has observed an 8% reduction in left ventricular wall thickness in treated diabetic groups, with improvements in cardiac energy metabolism Liver steatosis models studies in Cell Reports (2024) found MOTS-c treatments reduced NASH-diet-induced liver steatosis, apoptosis, inflammation, and fibrosis Pancreatic islet protection MOTS-c has been studied for its role in reducing pancreatic islet senescence and improving glucose intolerance in diabetes models Oxidative stress regulation acts on NRF2 and antioxidant response elements (ARE), enhancing cellular resistance to oxidative damage Bone metabolism emerging research has explored MOTS-cs role in osteoblast and osteoclast regulation in bone remodelling studies What Do Studies Say About MOTS-c Peptide
The only restriction for this ingredient is environmental
CagriSema, as of mid-2026, has no marketing approval from the FDA, the EMA, or any other regulator
